Pulmonary Embolism

Clinical Trial Finder

Many patients with pulmonary embolism are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Two-Site Compression POINt-OF-CARE Ultrasonography for DVT

Conditions:   Deep Vein Thrombosis;   Point of Care Ultrasound
Intervention:   Diagnostic Test: point of care ultrasound
Sponsor:   Jewish General Hospital
Not yet recruiting - verified February 2017

Randomized Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

Conditions:   Pulmonary Embolism;   Thrombotic Disease
Interventions:   Drug: DS-1040b;   Drug: placebo
Sponsors:   Daiichi Sankyo Inc.;   International Trial Expertise and Advisory Servies (ITREAS);   Medpace, Inc.
Recruiting - verified February 2017

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Condition:   Thromboembolism
Interventions:   Drug: Dabigatran etexilate;   Drug: Warfarin
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Conditions:   Cancer;   Venous Thromboembolism;   Deep Vein Thrombosis (DVT);   Pulmonary Embolism (PE);   Blood Clot
Interventions:   Drug: Rivaroxaban;   Drug: Apixaban;   Drug: Edoxaban;   Drug: Dabigatran;   Drug: Warfarin;   Drug: Dalteparin;   Drug: Enoxaparin;   Drug: Fondaparinux
Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute
Recruiting - verified February 2017

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer

Condition:   Venous Thrombosis and Pulmonary Embolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified February 2017

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Condition:   Venous Thromboembolism
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis

Conditions:   Symptomatic Aortic Stenosis;   Eligible for Transcatheter Aortic Valve Replacement
Interventions:   Drug: Apixaban;   Drug: Standard of care
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Action Research Group;   Bristol-Meyers Squibb & Pfizer
Recruiting - verified February 2017

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban;   Drug: Standard-of-care
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Active, not recruiting - verified February 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified February 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified February 2017

Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC

Condition:   Renal Cell Carcinoma
Intervention:   Radiation: Stereotactic ablative radiation therapy
Sponsor:   University of Texas Southwestern Medical Center
Recruiting - verified February 2017

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Pegylated (PEG) L-Asparaginase

Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2017

Long Term Outcomes of Venous Thromboembolism

Conditions:   Post Thrombotic Syndrome;   Chronic Thromboembolic Pulmonary Hypertension;   Venous Thrombosis
Intervention:  
Sponsor:   Ostfold Hospital Trust
Recruiting - verified February 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2017

Cook IVC Filter Study

Condition:   Pulmonary Embolism
Intervention:   Device: Günther Tulip® Vena Cava Filter and Cook Celect® Vena Cava Filters
Sponsor:   Cook
Recruiting - verified February 2017

Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Condition:   Anticoagulation
Intervention:   Drug: Apixaban
Sponsors:   Bristol-Myers Squibb;   Pfizer
Recruiting - verified August 2016

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients

Condition:   Embolism
Interventions:   Drug: Certoparin;   Drug: Heparin
Sponsor:   Novartis Pharmaceuticals
Completed - verified February 2017